• About
  • Services
  • Clients
  • Client News
  • PCG Research
  • PCG Digital
  • Contact
  • follow:

  • 12 Jun

    Quoin Pharmaceuticals Announces Signing of Research Agreement with University College Cork (UCC), Ireland

    ASHBURN, Va., June 12, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, today announced that it has signed a research agreement with The School of Pharmacy at University College Cork, Ireland. The scope of the… Read More..

    Share this:
  • 5 Jun

    Dosing Continues in Lexaria’s Second GLP-1 Human Pilot Study

    KELOWNA, BC / ACCESSWIRE / June 5, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that human pilot study #2, GLP-1-H24-2, (the "Study") continues to make progress and the second round of dosing for all nine study participants is now… Read More..

    Share this:
  • 4 Jun

    Equillium Announces Positive Topline Data from Phase 2 Study of EQ101 in Alopecia Areata

    LA JOLLA, Calif., June 04, 2024--(BUSINESS WIRE)--Equillium Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced positive topline data from its Phase 2, single dose, proof-of-concept (PoC) study of EQ101 in adult patients… Read More..

    Share this:
« Previous 1 … 68 69 70 71 72 … 239 Next »
  • Twitter feed is not available at the moment.
  • QUICK LINKS

    • About
    • Services
    • Clients
    • Client Media
    • PCG Media
    • PCG Research
    • Contact
    • Privacy Policy
    • Disclosures

    FOLLOW US

    Copyright © 2022 PCG Advisory.

    MENU logo
    • About
    • Services
    • Clients
    • Client News
    • PCG Research
    • PCG Digital
    • Contact